A new RSV antibody treatment, Nirsevimab, is available for newborns and infants ages 0 to 19 months. Nirsevimab helps infants build antibodies that protect against severe RSV.
Download our factsheet to learn more.
A new RSV antibody treatment, Nirsevimab, is available for newborns and infants ages 0 to 19 months. Nirsevimab helps infants build antibodies that protect against severe RSV.
Download our factsheet to learn more.